Tags:BioTechCommerceDevelopmentDrug
Biotech company built around a Phase 2/3 ready asset from NIH / NCATS, cyclodextrin, for the treatment of Niemann-Pick C (NPC)
Investors 2
Funding Rounds 2
Mentions in press and media 10
| Date | Title | Description | Category | Author | Source |
| 03.04.2017 | Cydan Deve... | Link to Release
Cambridge, ... | - | - | baycitycap... |
| 03.04.2017 | Sucampo Ph... | Vtesse, Inc., a Gaithersburg, ... | USA | - | finsmes.co... |
| 26.07.2016 | Vtesse Sec... | Gaithersburg, MD – Vtesse, Inc... | - | - | baycitycap... |
| 25.07.2016 | Vtesse Sec... | Vtesse, Inc., a Gaithersburg, ... | USA | - | finsmes.co... |
| 25.07.2016 | Vtesse Sec... | Vtesse, Inc., a company commit... | - | - | citybizlis... |
| 25.07.2016 | Vtesse Ink... |
GAITHERSBURG, MD, Company co... | - | - | vcnewsdail... |
| 19.08.2015 | Rare disea... | This could be a real blow for ... | - | - | medcitynew... |
| 07.01.2015 | Vtesse Lau... |
GAITHERSBURG, MD, Rare disea... | - | - | vcnewsdail... |
| 07.01.2015 | Vtesse Rai... | Vtesse, Inc., a Gaithersburg, ... | USA | - | finsmes.co... |
| - | Rare disea... | As companies turn to rare dise... | - | - | medcitynew... |